Table 1.
Baseline Characteristics of Study Population
| Variable | % (n) |
|---|---|
| Sex | |
| Female | 64.38 (1,706) |
| Male | 35.62 (944) |
| Age (years) | |
| < 15 | 6.26 (144) |
| 16-45 | 80.0 (2120) |
| > 45 | 13.74 (364) |
| Baseline CD4 | |
| < = 200 | 58.72 (1556) |
| 200 - 350 | 26.68 (707) |
| > 350 | 14.60 (387) |
| Median baseline CD4 (IQR) | 172 (85-275) |
| Baseline WHO Staging* | |
| Stage I | 27.36 (725) |
| Stage II | 26.60 (705) |
| Stage III | 40.23 (1066) |
| Stage IV | 4.08 (108) |
| ART Regimen | |
| NRTI Backbone | |
| Zidovudine based | 51.85 (1374) |
| Stavudine based | 46.15 (1223) |
| Tenofovir based | 1.74 (46) |
| Others | 0.26 (7) |
| NNRTI Backbone | |
| Nevirapine_based | 80.04 (2121) |
| Efavirenze_based | 19.96 (529) |
* Total do not add up to 114 due to missing data